Showing 571-580 of 618 results for "".
- Bausch + Lomb Launches Opal Digital Marketplace in the UShttps://modernod.com/news/bausch-lomb-launches-opal-digital-marketplace-in-the-us/2482465/Bausch + Lomb announced the US launch of Opal, a new digital e-commerce marketplace designed to enhance efficiency for eye care practices while improving the patient experience. The platform provides a streamlined and user-friendly ordering process for Bausch + Lomb’s contact lens
- Opthea Completes Manufacturing Milestone for Wet AMD Treatmenthttps://modernod.com/news/opthea-completes-manufacturing-milestone-for-wet-amd-treatment/2482447/Opthea announced the successful completion of its drug substance Process Performance Qualification (PPQ) campaign for sozinibercept, its lead candidate for treating wet age-related macular degeneration (AMD). The PPQ campaign involved the production of three consecutive commercial-scale
- Visionix Unveils the VX 610 Automated Fundus Camerahttps://modernod.com/news/visionix-unveils-the-vx-610-automated-fundus-camera/2482407/Visionix USA announced the launch of the VX 610 non-mydriatic automated fundus camera. The VX 610 boasts a range of automated features, including auto alignment, auto focus, and auto capture. This level of automation not only streamlines the imaging process but also redu
- J-Code for Glaukos’ iDose TR Becomes Activehttps://modernod.com/news/cms-j-code-for-glaukos-idose-tr-becomes-active/2482340/Glaukos announced that the CMS Healthcare Common Procedure Coding System’s J-code—J7355—for the company’s iDose TR is effective. The J-code provides patient access and streamlines the coverage and payment process as Glaukos advances its commercial launch of the treatment.<
- Harrow Provides Triesence Relaunch Updatehttps://modernod.com/news/harrow-provides-triesence-relaunch-update/2482325/Harrow has announced the manufacture of the first of three commercial-scale process performance qualification (PPQ) batches of Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is FDA‑approved for visualization during vitrec
- CoFi Announces Market-Wide Availability of its Multi-Provider Financing Solution with CareCredithttps://modernod.com/news/cofi-announces-market-wide-availability-of-its-multi-provider-financing-solution-with-carecredit/2482133/CoFi announced that patient payments with the CareCredit credit card can now be processed through CoFi’s multi-party payments platform. This market-wide availability follows a successful beta period involving joint CoFi and CareCredit customers. “We’ve
- LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patientshttps://modernod.com/news/lumithera-provides-update-on-fda-review-of-valeda-treatment-for-dry-amd-patients/2482040/LumiThera announced an update on the regulatory status of the Valeda Light Delivery System. Following feedback from the FDA, a De Novo request to reclassify the Valeda Light Delivery System as a Class II device has been submitted for review. Under the De Novo request process, the V
- Study of Sickle Retinopathy in Children Shows Similar Rate of Occurence as Adultshttps://modernod.com/news/study-of-sickle-retinopathy-in-children-shows-similar-rate-of-occurence-as-adults/2481945/The American Academy of Ophthalmology (AAO) announced the presentations of a study of sickle retinopathy, an age-dependent process that can develop in patients with sickle cell disease, of whom older patients are at substantially higher risk than younger patients. To learn more about ho
- NEI: Scientists Discover External Protein Network Can Help Stabilize Neural Connectionshttps://modernod.com/news/nei-scientists-discover-external-protein-network-can-help-stabilize-neural-connections/2481781/The Noelin family of secreted proteins bind to the external portion of AMPA glutamate receptors and stabilize them on the neuronal cellular membrane, a process necessary for transmission of full-strength signals between neurons, according to a study in mice from the National Eye Institute (NEI) a
- Marinomed Biotech to Launch Carragelose Eye Drops in Europe in 2024https://modernod.com/news/marinomed-biotech-to-launch-carragelose-eye-drops-in-europe-in-2024/2481677/Marinomed Biotech announced it plans to introduce a new Carragelose eye drop product (MAM-1001-3) with an expected market launch in Austria targeted for the first half of 2024. Marinomed said it has started a business development process to identify partners for the marketing of the product